Effect of Intermittent Administration of Teriparatide (Parathyroid Hormone 1-34) on Bone Morphogenetic Protein-Induced Bone Formation in a Rat Model of Spinal Fusion.

Morimoto T, Kaito T, Kashii M, Matsuo Y, Sugiura T, Iwasaki M, Yoshikawa H

The Journal of bone and joint surgery. American volume2 Jul 2014Cited by 38 (Europe PMC)

PMID24990981DOI10.2106/jbjs.m.01097PepBankPUB-24990981

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats receiving 2 μg rhBMP-2, adding PTH increased spinal fusion rate from 57% to 100% versus saline.
In plain wordsIn rats receiving 2 μg rhBMP-2, adding PTH increased spinal fusion from 57% to 100% compared with saline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFusion rate with low-dose rhBMP-2
Study
ratn: not reported in source
rhBMP-2 spinal fusion
Comparator
2 μg rhBMP-2 plus saline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
180 μg/kg/wk · injection · Two weeks before to six weeks after operationAs given in this study (rat).
Source sentences
Summary
The fusion rate in the group treated with 2 μg of rhBMP-2 significantly increased (from 57% to 100%) with the administration of parathyroid hormone 1-34 (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of forty-eight male Sprague-Dawley rats underwent posterolateral lumbar spinal arthrodesis with one of three different treatments with recombinant human (rh) BMP-2: (1) 0 μg (control), (2) 2 μg (low dose), or (3) 50 μg (high dose).
Summary · context
Each of the rhBMP-2 treatments was studied in combination with intermittent injections of either parathyroid hormone 1-34 (180 μg/kg/wk) or saline solution starting two weeks before the operation and continuing until six weeks after the operation.
Report a problemFND-2499098101
02AnimalAnimal study (in vivo)Efficacy outcome
In rats receiving no rhBMP-2, adding PTH did not significantly change spinal fusion rate versus saline.
In plain wordsIn rats receiving no rhBMP-2, adding PTH did not significantly change spinal fusion compared with saline.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFusion rate without rhBMP-2
Study
ratn: not reported in source
rhBMP-2 spinal fusion
Comparator
0 μg rhBMP-2 plus saline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
180 μg/kg/wk · injection · Two weeks before to six weeks after operationAs given in this study (rat).
Source sentences
Summary
The fusion rates in the other groups did not change significantly with the administration of parathyroid hormone 1-34.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of forty-eight male Sprague-Dawley rats underwent posterolateral lumbar spinal arthrodesis with one of three different treatments with recombinant human (rh) BMP-2: (1) 0 μg (control), (2) 2 μg (low dose), or (3) 50 μg (high dose).
Summary · context
Each of the rhBMP-2 treatments was studied in combination with intermittent injections of either parathyroid hormone 1-34 (180 μg/kg/wk) or saline solution starting two weeks before the operation and continuing until six weeks after the operation.
Report a problemFND-2499098102
03AnimalAnimal study (in vivo)Efficacy outcome
In rats receiving high-dose rhBMP-2, adding PTH did not significantly change spinal fusion rate versus saline.
In plain wordsIn rats receiving high-dose rhBMP-2, adding PTH did not significantly change spinal fusion compared with saline.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFusion rate with high-dose rhBMP-2
Study
ratn: not reported in source
rhBMP-2 spinal fusion
Comparator
50 μg rhBMP-2 plus saline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
180 μg/kg/wk · injection · Two weeks before to six weeks after operationAs given in this study (rat).
Source sentences
Summary
The fusion rates in the other groups did not change significantly with the administration of parathyroid hormone 1-34.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of forty-eight male Sprague-Dawley rats underwent posterolateral lumbar spinal arthrodesis with one of three different treatments with recombinant human (rh) BMP-2: (1) 0 μg (control), (2) 2 μg (low dose), or (3) 50 μg (high dose).
Summary · context
Each of the rhBMP-2 treatments was studied in combination with intermittent injections of either parathyroid hormone 1-34 (180 μg/kg/wk) or saline solution starting two weeks before the operation and continuing until six weeks after the operation.
Report a problemFND-2499098103
04AnimalAnimal study (in vivo)Efficacy outcome
In rats receiving 2 μg rhBMP-2, adding PTH significantly increased newly formed bone volume density versus saline.
In plain wordsIn rats receiving 2 μg rhBMP-2, adding PTH increased newly formed bone volume density compared with saline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone volume density with low-dose rhBMP-2
Study
ratn: not reported in source
rhBMP-2 spinal fusion
Comparator
2 μg rhBMP-2 plus saline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
180 μg/kg/wk · injection · Two weeks before to six weeks after operationAs given in this study (rat).
Source sentences
Summary
The bone volume density of the newly formed bone significantly increased in both the 2-μg and 50-μg rhBMP-2 treatment groups with the administration of parathyroid hormone 1-34 (p < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of forty-eight male Sprague-Dawley rats underwent posterolateral lumbar spinal arthrodesis with one of three different treatments with recombinant human (rh) BMP-2: (1) 0 μg (control), (2) 2 μg (low dose), or (3) 50 μg (high dose).
Summary · context
Each of the rhBMP-2 treatments was studied in combination with intermittent injections of either parathyroid hormone 1-34 (180 μg/kg/wk) or saline solution starting two weeks before the operation and continuing until six weeks after the operation.
Report a problemFND-2499098104
05AnimalAnimal study (in vivo)Efficacy outcome
In rats receiving 50 μg rhBMP-2, adding PTH significantly increased newly formed bone volume density versus saline.
In plain wordsIn rats receiving 50 μg rhBMP-2, adding PTH increased newly formed bone volume density compared with saline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone volume density with high-dose rhBMP-2
Study
ratn: not reported in source
rhBMP-2 spinal fusion
Comparator
50 μg rhBMP-2 plus saline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
180 μg/kg/wk · injection · Two weeks before to six weeks after operationAs given in this study (rat).
Source sentences
Summary
The bone volume density of the newly formed bone significantly increased in both the 2-μg and 50-μg rhBMP-2 treatment groups with the administration of parathyroid hormone 1-34 (p < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of forty-eight male Sprague-Dawley rats underwent posterolateral lumbar spinal arthrodesis with one of three different treatments with recombinant human (rh) BMP-2: (1) 0 μg (control), (2) 2 μg (low dose), or (3) 50 μg (high dose).
Summary · context
Each of the rhBMP-2 treatments was studied in combination with intermittent injections of either parathyroid hormone 1-34 (180 μg/kg/wk) or saline solution starting two weeks before the operation and continuing until six weeks after the operation.
Report a problemFND-2499098105

Studies that did not test the peptide alone2

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

06AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In rats undergoing spinal fusion, micro-CT showed abundant trabecular bone formation in the PTH treatment group.
In plain wordsIn rats undergoing spinal fusion, scans showed abundant trabecular bone formation in the PTH treatment group.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular bone formation
Study
ratn: not reported in source
rhBMP-2 spinal fusion
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Micro-computed tomography scans of the newly formed bone clearly demonstrated an abundance of trabecular bone formation in the group treated with parathyroid hormone 1-34.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of forty-eight male Sprague-Dawley rats underwent posterolateral lumbar spinal arthrodesis with one of three different treatments with recombinant human (rh) BMP-2: (1) 0 μg (control), (2) 2 μg (low dose), or (3) 50 μg (high dose).
Summary · context
Each of the rhBMP-2 treatments was studied in combination with intermittent injections of either parathyroid hormone 1-34 (180 μg/kg/wk) or saline solution starting two weeks before the operation and continuing until six weeks after the operation.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2499098106
07AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In rats undergoing spinal fusion, serum osteocalcin increased significantly in the PTH treatment group.
In plain wordsIn rats undergoing spinal fusion, blood osteocalcin increased significantly in the PTH treatment group.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSerum osteocalcin
Study
ratn: not reported in source
rhBMP-2 spinal fusion
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In addition, serum levels of osteocalcin were significantly increased in the parathyroid hormone 1-34 treatment group.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of forty-eight male Sprague-Dawley rats underwent posterolateral lumbar spinal arthrodesis with one of three different treatments with recombinant human (rh) BMP-2: (1) 0 μg (control), (2) 2 μg (low dose), or (3) 50 μg (high dose).
Summary · context
Each of the rhBMP-2 treatments was studied in combination with intermittent injections of either parathyroid hormone 1-34 (180 μg/kg/wk) or saline solution starting two weeks before the operation and continuing until six weeks after the operation.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2499098107

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.